Tarsal Coalition Market Size, Epidemiology, In-Market Drugs Sales, Pipeline Therapies, and Regional Outlook 2026-2036

Market Overview:

The tarsal coalition market reached a value of USD 560.8 Million across the top 7 markets (US, EU4, UK, and Japan) in 2025. Looking forward, IMARC Group expects the top 7 major markets to reach USD 890.8 Million by 2036, exhibiting a growth rate (CAGR) of 4.17% during 2026-2036.

The tarsal coalition market has been comprehensively analyzed in IMARC's new report titled "Tarsal Coalition Market Size, Epidemiology, In-Market Drugs Sales, Pipeline Therapies, and Regional Outlook 2026-2036". Tarsal coalition is an irregular connecting bridge of tissue between two typically distinct tarsal (foot) bones. It is often considered a type of birth abnormality. Tarsal coalitions are classified into two types: calcaneo-navicular (calcaneonavicular bar) and talo-calcaneal (talocalcaneal bar), which account for 90% of all coalitions. The symptoms of this disease usually appear in late childhood or early adolescence, manifesting as pain and stiffness in the foot and ankle, potentially leading to a rigid flatfoot and trouble walking, especially on uneven surfaces. Individuals suffering from the ailment might also experience frequent ankle sprains, limping, and muscle spasms in the leg. The diagnostic evaluation of the tarsal coalition is based on a comprehensive medical history, along with a physical exam. The healthcare professional might also recommend magnetic resonance imaging (MRI), which uses a combination of large magnets, radiofrequencies, and a computer to produce detailed images of organs, soft tissues, muscles, ligaments and other structures within the body. In some cases, a next-generation sequencing (NGS) test is performed that identifies mutations in specific genes associated with the condition.

To get more information on this market Request Sample

The escalating prevalence of NOG gene mutation that disrupts the normal prenatal development of bones in the foot is primarily driving the tarsal coalition market. In addition to this, the inflating utilization of nonsteroidal anti-inflammatory drugs (NSAIDs), such as ibuprofen or naproxen, in order to manage pain and inflammation in patients is also creating a positive outlook for the market. Moreover, the widespread adoption of physical therapy on account of its several advantages, like improved range of motion, enhanced muscle strength, and better foot function, is further bolstering the market growth. Apart from this, the rising usage of orthotics, including custom-made shoe inserts and arch supports, which can help distribute weight evenly across the foot, thereby reducing stress on the affected bones and joints, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of arthroscopic techniques, since they offer a minimally invasive approach with potential benefits like smaller incisions, reduced postoperative pain, and faster recovery, is expected to drive the tarsal coalition market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the tarsal coalition market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for tarsal coalition and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the tarsal coalition market in any manner.

Time Period of the Study

• Base Year: 2025
• Historical Period: 2020-2025
• Market Forecast: 2026-2036

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the tarsal coalition market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the tarsal coalition market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current tarsal coalition marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance

Key Questions Answered in this Report:

Market Insights

• How has the tarsal coalition market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2025 and how are they expected to perform till 2036?
• What was the country-wise size of the tarsal coalition market across the seven major markets in 2025 and what will it look like in 2036?
• What is the growth rate of the tarsal coalition market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?

Epidemiology Insights

• What is the number of prevalent cases (2020-2036) of tarsal coalition across the seven major markets?
• What is the number of prevalent cases (2020-2036) of tarsal coalition by age across the seven major markets?
• What is the number of prevalent cases (2020-2036) of tarsal coalition by gender across the seven major markets?
• How many patients are diagnosed (2020-2036) with tarsal coalition across the seven major markets?
• What is the size of the tarsal coalition patient pool (2020-2025) across the seven major markets?
• What would be the forecasted patient pool (2026-2036) across the seven major markets?
• What are the key factors driving the epidemiological trend of tarsal coalition?
• What will be the growth rate of patients across the seven major markets?

Tarsal Coalition: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for tarsal coalition drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the tarsal coalition market?
• What are the key regulatory events related to the tarsal coalition market?
• What is the structure of clinical trial landscape by status related to the tarsal coalition market?
• What is the structure of clinical trial landscape by phase related to the tarsal coalition market?
• What is the structure of clinical trial landscape by route of administration related to the tarsal coalition market?